Invalidity dossier
US 12109205
Methods of treating Fabry patients having renal impairment
Current assignee: Amicus Therapeutics Inc
Added 9/21/2026, 9:43:02 AM
Active provider: DeepSeek · deepseek-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
Patent Overview: US 12109205 B2
Title: Methods of treating Fabry patients having renal impairment
Patent number: US 12109205 B2
Application number: US 17/078,840
Inventors: Jeff Castelli; Elfrida Benjamin
Assignee: Amicus Therapeutics Inc. (original and current assignee, per the source)
Priority date: 2017-05-30
Filing date: 2020-10-23
Publication date (grant): 2024-10-08
Legal status: Active, with an adjusted expiration of 2039-05-02 (source notes legal status is an assumption, not a legal conclusion).
Purpose: The patent relates generally to using pharmacological chaperones to treat Fabry disease, particularly in patients with varying degrees of renal impairment. Fabry disease is described as a lysosomal storage disorder caused by a mutation in the GLA gene encoding α-galactosidase A (α-Gal A), leading to accumulation of the substrate globotriaosylceramide (GL-3). The described treatment uses migalastat, a small-molecule chaperone, and can include stabilizing renal function, reducing left ventricular mass index (LVMi), reducing plasma lyso-Gb3, and/or increasing α-Gal A activity.
Plain-language scope: One described aspect is a method of treating Fabry disease in a patient with renal impairment by administering an effective amount of migalastat or a salt thereof once every other day. The effective amount is described as about 100 mg to about 150 mg free base equivalent (FBE); specific examples include about 123 mg FBE, about 123 mg migalastat free base, and about 150 mg migalastat hydrochloride. The patient may have mild, moderate, or severe renal impairment; may be ERT-experienced or ERT-naïve; and may have proteinuria below 100 mg/24 hr, 100–1,000 mg/24 hr, or above 1,000 mg/24 hr. Administration may be oral (tablet, capsule, or solution) for at least 28 days, 6 months, or 12 months. Another aspect covers use of migalastat to stabilize renal function in a Fabry patient with renal impairment.
Source: https://patents.google.com/patent/US12109205/en
What the excerpt does not establish: It does not provide the full claims, complete specification, examples, or data; the excerpt is expressly partial and directs readers to the source for omitted text. It also does not establish claim scope, validity, or the accuracy of dates, assignee listings, or legal status, which the source itself identifies as assumptions or non-conclusions.
Generated 10/1/2026, 10:01:54 PM
Cases on file (0)
Specific litigation cases in our database that name US patent 12109205. The free-form analysis below may also discuss cases beyond this list.
No cases on file mention this patent. Upload a CSV or add a case manually in Admin → Manage litigation cases.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.